1a30: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
New page: left|200px<br /> <applet load="1a30" size="450" color="white" frame="true" align="right" spinBox="true" caption="1a30, resolution 2.0Å" /> '''HIV-1 PROTEASE COMPL...
 
OCA (talk | contribs)
No edit summary
Line 1: Line 1:
[[Image:1a30.gif|left|200px]]<br />
[[Image:1a30.gif|left|200px]]<br /><applet load="1a30" size="350" color="white" frame="true" align="right" spinBox="true"  
<applet load="1a30" size="450" color="white" frame="true" align="right" spinBox="true"  
caption="1a30, resolution 2.0&Aring;" />
caption="1a30, resolution 2.0&Aring;" />
'''HIV-1 PROTEASE COMPLEXED WITH A TRIPEPTIDE INHIBITOR'''<br />
'''HIV-1 PROTEASE COMPLEXED WITH A TRIPEPTIDE INHIBITOR'''<br />


==Overview==
==Overview==
The HIV-1 transframe region (TFR) is between the structural and functional, domains of the Gag-Pol polyprotein, flanked by the nucleocapsid and the, protease domains at its N and C termini, respectively. Transframe, octapeptide (TFP) Phe-Leu-Arg-Glu-Asp-Leu-Ala-Phe, the N terminus of TFR, and its analogues are competitive inhibitors of the action of the mature, HIV-1 protease. The smallest, most potent analogues are tripeptides:, Glu-Asp-Leu and Glu-Asp-Phe with Ki values of approximately 50 and, approximately 20 microM, respectively. Substitution of the acidic amino, acids in the TFP by neutral amino acids and d or retro-d configurations of, Glu-Asp-Leu results in an &gt;40-fold increase in Ki. Protease inhibition by, Glu-Asp-Leu is dependent on a protonated form of a group with a pKa of, 3.8; unlike other inhibitors of HIV-1 protease which are highly, hydrophobic, Glu-Asp-Leu is extremely soluble in water, and its binding, affinity decreases with increasing NaCl concentration. However, Glu-Asp-Leu is a poor inhibitor (Ki approximately 7.5 mM) of the mammalian, aspartic acid protease pepsin. X-ray crystallographic studies at pH 4.2, show that the interactions of Glu at P2 and Leu at P1 of Glu-Asp-Leu with, residues of the active site of HIV-1 protease are similar to those of, other product-enzyme complexes. It was not feasible to understand the, interaction of intact TFP with HIV-1 protease under conditions of crystal, growth due to its hydrolysis giving rise to two products. The, sequence-specific, selective inhibition of the HIV-1 protease by the viral, TFP suggests a role for TFP in regulating protease function during HIV-1, replication.
The HIV-1 transframe region (TFR) is between the structural and functional domains of the Gag-Pol polyprotein, flanked by the nucleocapsid and the protease domains at its N and C termini, respectively. Transframe octapeptide (TFP) Phe-Leu-Arg-Glu-Asp-Leu-Ala-Phe, the N terminus of TFR, and its analogues are competitive inhibitors of the action of the mature HIV-1 protease. The smallest, most potent analogues are tripeptides: Glu-Asp-Leu and Glu-Asp-Phe with Ki values of approximately 50 and approximately 20 microM, respectively. Substitution of the acidic amino acids in the TFP by neutral amino acids and d or retro-d configurations of Glu-Asp-Leu results in an &gt;40-fold increase in Ki. Protease inhibition by Glu-Asp-Leu is dependent on a protonated form of a group with a pKa of 3.8; unlike other inhibitors of HIV-1 protease which are highly hydrophobic, Glu-Asp-Leu is extremely soluble in water, and its binding affinity decreases with increasing NaCl concentration. However, Glu-Asp-Leu is a poor inhibitor (Ki approximately 7.5 mM) of the mammalian aspartic acid protease pepsin. X-ray crystallographic studies at pH 4.2 show that the interactions of Glu at P2 and Leu at P1 of Glu-Asp-Leu with residues of the active site of HIV-1 protease are similar to those of other product-enzyme complexes. It was not feasible to understand the interaction of intact TFP with HIV-1 protease under conditions of crystal growth due to its hydrolysis giving rise to two products. The sequence-specific, selective inhibition of the HIV-1 protease by the viral TFP suggests a role for TFP in regulating protease function during HIV-1 replication.


==About this Structure==
==About this Structure==
1A30 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1]. Active as [http://en.wikipedia.org/wiki/HIV-1_retropepsin HIV-1 retropepsin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.23.16 3.4.23.16] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1A30 OCA].  
1A30 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1]. Active as [http://en.wikipedia.org/wiki/HIV-1_retropepsin HIV-1 retropepsin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.23.16 3.4.23.16] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1A30 OCA].  


==Reference==
==Reference==
Line 15: Line 14:
[[Category: Human immunodeficiency virus 1]]
[[Category: Human immunodeficiency virus 1]]
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Davies, D.R.]]
[[Category: Davies, D R.]]
[[Category: Dyda, F.]]
[[Category: Dyda, F.]]
[[Category: Kimmel, A.R.]]
[[Category: Kimmel, A R.]]
[[Category: Louis, J.M.]]
[[Category: Louis, J M.]]
[[Category: Nashed, N.T.]]
[[Category: Nashed, N T.]]
[[Category: aspartic protease]]
[[Category: aspartic protease]]
[[Category: complex (aspartic protease/inhibitor)]]
[[Category: complex (aspartic protease/inhibitor)]]
[[Category: hiv protease]]
[[Category: hiv protease]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Thu Nov  8 13:48:59 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 11:40:15 2008''